|
|
|
BSX Dividend History & Description — Boston Scientific Corp.
Boston Scientific develops, manufactures and markets medical devices used in a range of interventional medical specialties. Co.'s MedSurg segment includes: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat urological and pelvic conditions, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, incontinence and pelvic floor disorders. Co.'s Rhythm and Neuro segment develops and manufactures a range of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Preferred: BSX.PRA When considering the Boston Scientific Corp. stock dividend history, we have taken known splits into account, such that the BSX dividend history is presented on a split-adjusted ("apples to apples") basis. Boston Scientific Corp. dividend history is presented both in graphical/chart form, and as a BSX dividend history data table along the right-hand column.
|
BSX Stock Dividend HistoryThe BSX dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable BSX historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the BSX dividend history record. Also see the BSX stock dividend history data table along the right-hand column below.
|
|
|
|
Quotes delayed 20 minutes
|
Strong Buy (3.71 out of 4)
71st percentile
|
PARTNER NEWS:Mon, Apr 29, 5:20 AM, Zacks
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
Wed, Apr 24, 10:40 AM, Zacks
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
|
|